Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 59.55 percent decrease over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $1.912 million which missed the analyst consensus estimate of $2.047 million by 6.61 percent.
Phathom Pharmaceuticals Q1 2024 GAAP EPS $(1.42) Misses $(1.28) Estimate, Sales $1.912M Miss $2.047M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.